Baricitinib Protects β-cell Function In New-Onset Type 1 Diabetes|

1. In this randomized controlled trial, the Janus kinase (JAK) inhibitor baricitinib was associated with preserved β-cell function compared to placebo in patients with new-onset type 1 diabetes mellitus (T1DM).
2. Patients receiving baricitinib also demonstrated tighter glycemic control compared to placebo.
#health
#healthtips
#youtubeviral